Benchmark analyst Bruce Jackson raised the firm’s price target on Harvard Bioscience (HBIO) to $6 from 60c and keeps a Speculative Buy rating on the shares after updating the firm’s model for the 1:10 reverse split enacted by Harvard Bioscience on Friday, March 13.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO:
- Upcoming Stock Splits This Week (March 16–20, 2026) – Stay Invested
- Harvard Bioscience trading halted, news pending
- Harvard Bioscience price target lowered to 60c from $2 at Benchmark
- Harvard Bioscience Earnings Call Signals Gradual Recovery
- Harvard Bioscience reports Q4 adjusted EPS (0c) vs 6c last year